Prolonged paralysis after long-term vecuronium infusion
Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with f...
Gespeichert in:
Veröffentlicht in: | Critical care medicine 1992-02, Vol.20 (2), p.304-306 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 306 |
---|---|
container_issue | 2 |
container_start_page | 304 |
container_title | Critical care medicine |
container_volume | 20 |
creator | VANDERHEYDEN, BETH A REYNOLDS, H NEAL GEROLD, KEVIN B EMANUELE, TULLIO |
description | Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (>3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion. |
doi_str_mv | 10.1097/00003246-199202000-00019 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00003246_199202000_00019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1346591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</originalsourceid><addsrcrecordid>eNp1kctOAyEUhonR1Fp9BJNZuEU5XGbK0jTekia60DU5ZcCOzqWBjk3fXurUupKEwOF8PwkfhGTAroHp4oalIbjMKWjNGU8VTRP0ERmDEqngWhyTMWOaUSG1OCVnMX4kQqpCjMgIhMyVhjEpXkJXd-27K7MVBqy3sYoZ-rUL2e6Ypk2TfTnbh66t-iarWt_HqmvPyYnHOrqL_Tohb_d3r7NHOn9-eJrdzqkVU6kp5xK8lLDgTIKzfoEonSq9Usg8ao6l1QJynArtXF46C3lCFbMgilJ4LSZkOtxrQxdjcN6sQtVg2BpgZqfC_KowBxXmR0WKXg7RVb9oXPkXHN6e-lf7PkaLtQ_Y2ioeMAWaKykSJgds09XJRvys-40LZumwXi_Nfx8hvgH3cXXR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prolonged paralysis after long-term vecuronium infusion</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</creator><creatorcontrib>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</creatorcontrib><description>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (>3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-199202000-00019</identifier><identifier>PMID: 1346591</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: Williams & Wilkins</publisher><subject>Adult ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Humans ; Infusions, Intravenous ; Intensive Care Units ; Male ; Medical sciences ; Paralysis - chemically induced ; Pharmacology. Drug treatments ; Respiration, Artificial ; Time Factors ; Toxicity: nervous system and muscle ; Vecuronium Bromide - administration & dosage ; Vecuronium Bromide - adverse effects</subject><ispartof>Critical care medicine, 1992-02, Vol.20 (2), p.304-306</ispartof><rights>Williams & Wilkins 1992. All Rights Reserved.</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5192543$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1346591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VANDERHEYDEN, BETH A</creatorcontrib><creatorcontrib>REYNOLDS, H NEAL</creatorcontrib><creatorcontrib>GEROLD, KEVIN B</creatorcontrib><creatorcontrib>EMANUELE, TULLIO</creatorcontrib><title>Prolonged paralysis after long-term vecuronium infusion</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (>3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Intensive Care Units</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Paralysis - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiration, Artificial</subject><subject>Time Factors</subject><subject>Toxicity: nervous system and muscle</subject><subject>Vecuronium Bromide - administration & dosage</subject><subject>Vecuronium Bromide - adverse effects</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOAyEUhonR1Fp9BJNZuEU5XGbK0jTekia60DU5ZcCOzqWBjk3fXurUupKEwOF8PwkfhGTAroHp4oalIbjMKWjNGU8VTRP0ERmDEqngWhyTMWOaUSG1OCVnMX4kQqpCjMgIhMyVhjEpXkJXd-27K7MVBqy3sYoZ-rUL2e6Ypk2TfTnbh66t-iarWt_HqmvPyYnHOrqL_Tohb_d3r7NHOn9-eJrdzqkVU6kp5xK8lLDgTIKzfoEonSq9Usg8ao6l1QJynArtXF46C3lCFbMgilJ4LSZkOtxrQxdjcN6sQtVg2BpgZqfC_KowBxXmR0WKXg7RVb9oXPkXHN6e-lf7PkaLtQ_Y2ioeMAWaKykSJgds09XJRvys-40LZumwXi_Nfx8hvgH3cXXR</recordid><startdate>199202</startdate><enddate>199202</enddate><creator>VANDERHEYDEN, BETH A</creator><creator>REYNOLDS, H NEAL</creator><creator>GEROLD, KEVIN B</creator><creator>EMANUELE, TULLIO</creator><general>Williams & Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199202</creationdate><title>Prolonged paralysis after long-term vecuronium infusion</title><author>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Intensive Care Units</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Paralysis - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiration, Artificial</topic><topic>Time Factors</topic><topic>Toxicity: nervous system and muscle</topic><topic>Vecuronium Bromide - administration & dosage</topic><topic>Vecuronium Bromide - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VANDERHEYDEN, BETH A</creatorcontrib><creatorcontrib>REYNOLDS, H NEAL</creatorcontrib><creatorcontrib>GEROLD, KEVIN B</creatorcontrib><creatorcontrib>EMANUELE, TULLIO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VANDERHEYDEN, BETH A</au><au>REYNOLDS, H NEAL</au><au>GEROLD, KEVIN B</au><au>EMANUELE, TULLIO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged paralysis after long-term vecuronium infusion</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>1992-02</date><risdate>1992</risdate><volume>20</volume><issue>2</issue><spage>304</spage><epage>306</epage><pages>304-306</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (>3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</abstract><cop>Hagerstown, MD</cop><pub>Williams & Wilkins</pub><pmid>1346591</pmid><doi>10.1097/00003246-199202000-00019</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-3493 |
ispartof | Critical care medicine, 1992-02, Vol.20 (2), p.304-306 |
issn | 0090-3493 1530-0293 |
language | eng |
recordid | cdi_crossref_primary_10_1097_00003246_199202000_00019 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Adult Biological and medical sciences Drug toxicity and drugs side effects treatment Humans Infusions, Intravenous Intensive Care Units Male Medical sciences Paralysis - chemically induced Pharmacology. Drug treatments Respiration, Artificial Time Factors Toxicity: nervous system and muscle Vecuronium Bromide - administration & dosage Vecuronium Bromide - adverse effects |
title | Prolonged paralysis after long-term vecuronium infusion |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A20%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20paralysis%20after%20long-term%20vecuronium%20infusion&rft.jtitle=Critical%20care%20medicine&rft.au=VANDERHEYDEN,%20BETH%20A&rft.date=1992-02&rft.volume=20&rft.issue=2&rft.spage=304&rft.epage=306&rft.pages=304-306&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/00003246-199202000-00019&rft_dat=%3Cpubmed_cross%3E1346591%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1346591&rfr_iscdi=true |